Do you doubt him ?, page-4

Also important to remember that Dr. Gunning is speaking of non-oncology opportunities for the ATM technology (which is what he is involved in). This has not yet been developed or exploited at all (at least the market hasn't been informed of any such developments that I know of yet). All non-oncology developments at Novogen up to now have been based on the SBP technology, which Dr. Kelly, Dr. Heaton, and Dr. Brown have been involved in. Non-oncology possibilities for the ATM platform aren't even on the Novogen diagram yet but could open up a whole new realm of possibilities. Certainly, a lot more effort would need to be devoted to R&D on that side for that to occur, though. But the potential seems limitless.